Novartis to Evaluate Quanterix Platform for Dx Use | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Quanterix said today it has entered an agreement with Novartis to evaluate its Single Molecule Array, or SiMoA, platform for diagnostic use.

The platform will be evaluated at Quanterix, based in Cambridge, Mass., and will focus on an undisclosed neuron-specific protein target. Financial and other terms of the deal were also undisclosed.

The SiMoA platform is used for the development and commercialization of blood tests that measure protein levels in blood.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.